Krystal Biotech, Inc.

Krystal Biotech, Inc.

Biotechnology • Healthcare • Pittsburgh, PA, United States • KRYS (NMS)

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

412 586 5830 2100 Wharton Street, Pittsburgh, PA 15203, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Krystal Biotech Announces Investor Conference Call for Interim Clinical Update on KB407 in Cystic Fibrosis Study - Quiver Quantitative
Quiver Quantitative • Jan 7
Early test data on an inhaled cystic fibrosis treatment to be revealed - Stock Titan
Stock Titan • Jan 7
Krystal Biotech And 2 Other Growth Stocks Insiders Are Betting On - Yahoo Finance
Yahoo Finance • Dec 12
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 5,800 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
MarketBeat • Jan 6
Krystal Biotech (KRYS) Receives Upgraded Rating and Price Target Boost from Citigroup | KRYS Stock News - GuruFocus
GuruFocus • Jan 6

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Krystal Biotech, Inc. had layoffs?
No layoff events have been recorded for Krystal Biotech, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Krystal Biotech, Inc. have?
Krystal Biotech, Inc. has approximately 275 employees.
What industry is Krystal Biotech, Inc. in?
Krystal Biotech, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Krystal Biotech, Inc. a publicly traded company?
Yes, Krystal Biotech, Inc. is publicly traded under the ticker symbol KRYS on the NMS. The company has a market capitalization of approximately $7.31 billion.
Where is Krystal Biotech, Inc. headquartered?
Krystal Biotech, Inc. is headquartered in Pittsburgh, PA, United States at 2100 Wharton Street, Pittsburgh, PA 15203, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.